Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections [PDF]
, 2006 Sabine Mumprecht +3 more
openalex +1 more source
Correction: Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet. [PDF]
PLoS One, 2022 PLOS ONE Editors.
europepmc +1 more source
Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis. [PDF]
Front Syst Neurosci, 2022 Perkins ME +3 more
europepmc +1 more source
A Case of Pathological CR after Imatinib Mesylate Therapy in a Rectal GIST
, 2017 Yuzo Fukuda +7 more
openalex +2 more sources
Pakistan Armed Forces Medical JournalObjective: To find the frequency of haematological response in patients of chronic myeloid leukaemia (Chronic Phase) after three months of Imatinib Mesylate therapy, presenting to CMH Rawalpindi Study Design: Cross-sectional study.
Anil Babar +6 more
doaj +1 more source
A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate [PDF]
, 2010 Min‐Sik Kim +10 more
openalex +1 more source
A rare complication of imatinib mesylate therapy: drug-induced pneumonitis
Терапевтический архив, 2010 The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease.
Ol'ga Veniaminovna Stakhina +7 more
doaj
Imatinib Mesylate Induces Necroptotic Cell Death and Impairs Autophagic Flux in Human Cardiac Progenitor Cells. [PDF]
Int J Mol Sci, 2022 Walmsley R +4 more
europepmc +1 more source